Premium
Effective dose of granisetron in the reduction of nausea and vomiting after breast surgery
Author(s) -
FLJJII Y.,
TANAKA H.,
TOYOOKA H.
Publication year - 1997
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/j.1399-6576.1997.tb04860.x
Subject(s) - granisetron , medicine , anesthesia , placebo , nausea , vomiting , postoperative nausea and vomiting , general anaesthesia , antiemetic , surgery , adverse effect , alternative medicine , pathology
Background: Prophylactic use of granisetron, a selective Shydroxytryptamine type 3 receptor antagonist, reduces the incidence of nausea and vomiting after breast surgery. This study was undertaken to determine the minimum effective dose of granisetron in the reduction of postoperative nausea and vomiting (PONV) in patients undergoing general anaesthesia for breast surgery. Methods: In a randomized, double‐blind manner, 120 female patients aged 42–66 years were assigned to receive either placebo (saline) or granisetron in a dose of 20 μg · kg ‐1 , 40 μg · kg ‐1 and 80 μg · kg ‐1 i.v. immediately before the induction of anaesthesia. A standard general anaesthetic technique was employed throughout. The POW and safety assessments were performed continuously during the first 24 h after anaesthesia. Results: There were no significant differences among the groups with regard to patient demographics, surgical procedures, anaesthetics administered and analgesics given. The incidence of PONV was 47%, 43%, 17% and 17% after administration of placebo and granisetron 20 μg ‐kg ‐1 , 40 μg kg ‐1 and 80 μg kg ‐1 , respectively. Granisetron 40 μg kg ‐1 was as effective as 80 μ g ‐ kg ‐1 and both resulted in significant reductions of the incidence of PONV compared with placebo and granisetron 20 μg kg ‐1 ( P < 0.05). No differences in the incidence of adverse events were observed among the groups. Conclusion: Granisetron 40 μg · kg ‐1 appears to be the minimum effective dose for reducing POW in patients undergoing general anaesthesia for breast surgery.